Begoña Bermejo

发表

NK cell-triggered CCL5/IFNγ-CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer

L. Comerma, S. Servitja, O. Arpí, 2024, Journal of experimental & clinical cancer research : CR.